Thymalin

The thymus is the organ responsible for producing naive T-cells — the immune system's frontline defenders. It begins involuting (shrinking and fatty degeneration) in the mid-20s and is largely non-functional by age 65. This collapse in naive T-cell output is a primary driver of immune senescence. Thymalin works by restoring thymic peptide signalling to partially reverse this involution.

Thymosin alpha-1 is a single purified thymic peptide. Thymalin is a broader thymic polypeptide extract containing the full spectrum of thymic signalling molecules, including thymosins, thymopentin, and thymulin. The extract's broader coverage may provide more comprehensive immune restoration.

The evidence base is strongest for older populations (60+) where thymic involution is most advanced. Younger users may see less dramatic immune effects, though thymalin is sometimes used in immunocompromised individuals regardless of age.

The most direct measurement is an immune cell panel: T-cell subset counts (CD4+, CD8+, naive vs. memory), NK cell activity, and general CBC with differential. These markers should be tested before starting and 4-8 weeks after a cycle for objective assessment.

Yes — the classic Russian longevity protocol runs both concurrently in 10-day cycles. They address complementary ageing mechanisms (immune involution for thymalin, telomere/pineal for epithalon) and show synergistic mortality reduction data in the long-term clinical studies.

Thymalin has been used clinically in immune-deficient populations and is generally well tolerated. However, individuals with autoimmune conditions should consult a physician before use, as T-cell restoration could theoretically amplify autoreactive immune responses.